X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (110627) 110627
Newspaper Article (4729) 4729
Newsletter (716) 716
Magazine Article (682) 682
Book Chapter (405) 405
Book / eBook (179) 179
Trade Publication Article (144) 144
Dissertation (94) 94
Web Resource (78) 78
Conference Proceeding (47) 47
Transcript (44) 44
Publication (33) 33
Book Review (25) 25
Reference (10) 10
Government Document (7) 7
Report (4) 4
Streaming Video (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (73605) 73605
male (44703) 44703
insulin (40710) 40710
female (39550) 39550
diabetes (32243) 32243
animals (31742) 31742
endocrinology & metabolism (25870) 25870
middle aged (23824) 23824
insulin resistance (23822) 23822
adult (23423) 23423
insulin - therapeutic use (23134) 23134
glucose (19448) 19448
hypoglycemic agents - therapeutic use (18847) 18847
insulin-resistance (16410) 16410
diabetes mellitus (15079) 15079
obesity (14848) 14848
aged (14533) 14533
type 2 diabetes (13710) 13710
diabetes mellitus, type 2 - drug therapy (13635) 13635
mice (13012) 13012
blood glucose - metabolism (12751) 12751
rats (11853) 11853
metabolism (11757) 11757
risk factors (11549) 11549
research (11012) 11012
pharmacology & pharmacy (9981) 9981
insulin - blood (9547) 9547
analysis (8930) 8930
health aspects (8767) 8767
proteins (8742) 8742
care and treatment (8567) 8567
adolescent (8424) 8424
hyperglycemia (8083) 8083
inflammation (8071) 8071
physiological aspects (7743) 7743
rodents (7714) 7714
diabetes mellitus, type 1 - drug therapy (7671) 7671
blood glucose - analysis (7485) 7485
metabolic syndrome (7318) 7318
insulin - metabolism (7260) 7260
medicine (7218) 7218
insulin - administration & dosage (7136) 7136
treatment outcome (7119) 7119
oxidative stress (7074) 7074
research article (6640) 6640
diabetes mellitus - drug therapy (6500) 6500
gene expression (6450) 6450
expression (6435) 6435
diabetes mellitus, type 2 - blood (6426) 6426
child (6264) 6264
studies (6176) 6176
mellitus (6076) 6076
body mass index (5988) 5988
medicine & public health (5917) 5917
multidisciplinary sciences (5900) 5900
internal medicine (5805) 5805
risk (5612) 5612
medicine, general & internal (5492) 5492
cell biology (5449) 5449
hypoglycemic agents - administration & dosage (5445) 5445
dextrose (5432) 5432
medicine, research & experimental (5392) 5392
time factors (5392) 5392
diet (5387) 5387
therapy (5342) 5342
hypoglycemia (5335) 5335
diabetes therapy (5292) 5292
mortality (5128) 5128
biochemistry & molecular biology (5118) 5118
lipids (5088) 5088
physiology (5071) 5071
glycemic control (5062) 5062
liver (5062) 5062
kinases (4946) 4946
patients (4839) 4839
disease (4820) 4820
metformin (4770) 4770
hypertension (4743) 4743
body weight (4683) 4683
science (4562) 4562
blood glucose - drug effects (4557) 4557
signal transduction (4510) 4510
glucose metabolism (4505) 4505
homeostasis (4464) 4464
type 1 diabetes (4452) 4452
apoptosis (4436) 4436
cholesterol (4367) 4367
nutrition & dietetics (4361) 4361
abridged index medicus (4309) 4309
drug therapy (4242) 4242
review (4179) 4179
clinical trials (4176) 4176
medical research (4166) 4166
glucose tolerance test (4143) 4143
metabolic disorders (4124) 4124
diabetes mellitus, type 2 - complications (4070) 4070
glucose - metabolism (4036) 4036
mice, inbred c57bl (4027) 4027
diabetes mellitus, type 2 - metabolism (3982) 3982
cancer (3962) 3962
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (73) 73
Online Resources - Online (49) 49
Collection Dvlpm't (Acquisitions) - Vendor file (20) 20
UofT at Mississauga - Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
St. Michael's Hospital - Stacks (3) 3
Gerstein Science - Circulation Desk (2) 2
Scarborough Hospital - Birchmount (2) 2
UofT at Scarborough - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Engineering & Comp. Sci. - Material is damaged (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
OISE - Theses (1) 1
Regis College - Stacks (1) 1
Robarts - Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Trinity College (John W Graham) - Storage (1) 1
UTL at Downsview - May be requested (1) 1
University College (Laidlaw) - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (111876) 111876
German (1515) 1515
French (1153) 1153
Japanese (909) 909
Russian (688) 688
Spanish (523) 523
Italian (411) 411
Chinese (370) 370
Polish (287) 287
Portuguese (149) 149
Czech (137) 137
Dutch (115) 115
Hungarian (96) 96
Danish (70) 70
Swedish (63) 63
Finnish (48) 48
Bulgarian (41) 41
Romanian (40) 40
Norwegian (34) 34
Hebrew (32) 32
Serbian (27) 27
Ukrainian (19) 19
Croatian (18) 18
Slovak (17) 17
Korean (12) 12
Turkish (10) 10
Arabic (8) 8
Lithuanian (7) 7
Afrikaans (2) 2
Indonesian (2) 2
Bosnian (1) 1
Breton (1) 1
Greek (1) 1
Icelandic (1) 1
Persian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLASMA-GLUCOSE | 7-36 AMIDE | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2011, Volume 121, Issue 1, pp. 308 - 317
...) as an important negative prognostic biomarker Given that CXCL10 mediates chemoattraction of activated lymphocytes, it is counter-intuitive that this chemokine correlates with therapeutic... 
MEDICINE, RESEARCH & EXPERIMENTAL | LIVER INFLAMMATION | GAMMA-INDUCIBLE PROTEIN-10 | VIRUS-INFECTION | DIPEPTIDYL-PEPTIDASE-IV | ANTIVIRAL THERAPY | INSULIN-RESISTANCE | IMMUNE-RESPONSES | CHRONIC HEPATITIS-C | LEVELS CORRELATE | PEGINTERFERON PLUS RIBAVIRIN | Chemokine CXCL10 - blood | Prognosis | Antiviral Agents - therapeutic use | Receptors, CXCR3 - blood | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Chemokine CXCL10 - antagonists & inhibitors | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Hepatitis C, Chronic - therapy | Recombinant Proteins | Hepatitis C, Chronic - blood | Polyethylene Glycols - therapeutic use | T-Lymphocytes - virology | Treatment Failure | Hepatitis C, Chronic - immunology | Peptide Fragments - blood | Protein Array Analysis | T-Lymphocytes - immunology | Proteases | Physiological aspects | Research | Diagnosis | Hepatitis C | Drug therapy | Chemokines | Hepatitis C, Chronic/therapy | T-Lymphocytes/immunology | Polyethylene Glycols/therapeutic use | Dipeptidyl Peptidase 4/blood | Receptors, CXCR3/blood | Chemokine CXCL10/blood | T-Lymphocytes/virology | Hepatitis C, Chronic/blood | Interferon-alpha/therapeutic use | Chemokine CXCL10/antagonists & inhibitors | Life Sciences | Immunology | Antiviral Agents/therapeutic use | Hepatitis C, Chronic/immunology | Peptide Fragments/blood | Ribavirin/therapeutic use | Hepatitis C, Chronic/virology
Journal Article
Diabetes technology & therapeutics, ISSN 1520-9156, 1999
Journal
Medical Clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | NOD MICE | ANTI-CD3 MONOCLONAL-ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | MEDICINE, GENERAL & INTERNAL | ISLET GRAFT-SURVIVAL | PHASE-II TRIAL | RECENT-ONSET | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article
European heart journal, ISSN 1522-9645, 2015, Volume 36, Issue 34, pp. 2288 - 2296
Journal Article
Drugs, ISSN 0012-6667, 07/2000, Volume 60, Issue 1, pp. 95 - 113
... (non-insulin-dependent) diabetes mellitus. The aim of this article is to briefly review the various therapeutic agents available for management of patients with type 2 diabetes mellitus and to suggest a potential approach to drug selection... 
Tolazamide, therapeutic use | Alpha glucosidase inhibitors, therapeutic use | Amylin agonists, therapeutic use | Acetohexamide, therapeutic use | Chlorpropamide, therapeutic use | Biguanides, therapeutic use | Tolbutamide, therapeutic use | Gliquidone, therapeutic use | Meglitinide, therapeutic use | Insulins, therapeutic use | Research and development | Glimepiride, therapeutic use | Type 2 diabetes mellitus, treatment | Glibenclamide, therapeutic use | Thiazolidinediones, therapeutic use | Sulphonylureas, therapeutic use | Gliclazide, therapeutic use | Glipizide, therapeutic use | Glucagon like peptide 1, therapeutic use | Antihyperglycaemics, therapeutic use | Insulin, therapeutic use | Insulin glargine, therapeutic use | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | ACTING INSULIN ANALOG | MIDDLE-AGED MEN | HUMAN AMYLIN ANALOG | PHARMACOLOGY & PHARMACY | TOXICOLOGY | IMPROVED GLYCEMIC CONTROL | PLACEBO-CONTROLLED TRIAL | DOUBLE-BLIND CROSSOVER | ALPHA-GLUCOSIDASE INHIBITION | HEART-DISEASE MORTALITY | MYOCARDIAL-INFARCTION DIGAMI | ORAL ANTIDIABETIC AGENTS | Hypoglycemic Agents - therapeutic use | Insulin - pharmacology | Diabetes Mellitus, Type 2 - physiopathology | Humans | Diabetes Mellitus, Type 2 - drug therapy | Forecasting | Insulin - therapeutic use | Hypoglycemic Agents - pharmacology
Journal Article
Diabetes care, ISSN 0149-5992, 2009, Volume 32, Issue 5, pp. 762 - 768
OBJECTIVE: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with... 
NON-INFERIORITY | GLYCEMIC CONTROL | SULFONYLUREA | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | BASAL INSULIN | GLUCOSE | ENDOCRINOLOGY & METABOLISM | SECRETION | MELLITUS | TWICE-DAILY EXENATIDE | Metformin - therapeutic use | C-Peptide - blood | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Exenatide | Female | Insulin - analogs & derivatives | Insulin Secretion | Body Mass Index | Hypoglycemic Agents - therapeutic use | Insulin-Secreting Cells - physiology | Insulin, Long-Acting | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Diabetes Mellitus, Type 2 - physiopathology | Insulin-Secreting Cells - drug effects | Insulin Glargine | Arginine - pharmacology | Venoms - therapeutic use | Kinetics | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Insulin - therapeutic use | Peptides - therapeutic use | Index Medicus | Original Research | Hemoglobin A | Insulin/analogs & derivatives/secretion/therapeutic use | Blood Glucose/metabolism | Type 2/blood/drug therapy/physiopathology | MEDICIN OCH HÄLSOVETENSKAP | Diabetes Mellitus | Insulin-Secreting Cells/drug effects/physiology | Venoms/therapeutic use | Metformin/therapeutic use | Glycosylated/metabolism | Peptides/therapeutic use | Arginine/pharmacology | Hypoglycemic Agents/therapeutic use | C-Peptide/blood | MEDICAL AND HEALTH SCIENCES
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 08/2017, Volume 102, Issue 8, pp. 3050 - 3055
Context: Delayed thyrotropin (TSH) elevation (dTSH) is defined as elevated TSH at the second neonatal screening (after normal TSH levels at the initial... 
THYROID-STIMULATING HORMONE | ENDOCRINOLOGY & METABOLISM | THYROTROPIN | Cefotaxime - therapeutic use | Ibuprofen - therapeutic use | Multivariate Analysis | Humans | Male | Neonatal Screening | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Anti-Bacterial Agents - therapeutic use | Furosemide - therapeutic use | Intensive Care Units, Neonatal | Time Factors | Female | Retrospective Studies | Infant, Newborn | Thyrotropin - blood | Dopamine - therapeutic use | Hypoglycemic Agents - therapeutic use | Sympathomimetics - therapeutic use | Infant, Low Birth Weight | Erythrocyte Transfusion | Pneumothorax - epidemiology | Risk Factors | Hypothyroidism - diagnosis | Respiration, Artificial | Cesarean Section | Ductus Arteriosus, Patent - epidemiology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Vancomycin - therapeutic use | Infant, Premature | Diuretics - therapeutic use | Hypothyroidism - blood | Insulin - therapeutic use | Neonates | Intensive care | Cefotaxime | Pathogenesis | Erythrocytes | Vancomycin | Multivariate analysis | Risk factors | Red blood cells | Ibuprofen | Cesarean section | Thyroid | Pneumothorax | Dopamine | Low-birth-weight | Fluconazole | Blood cells | Risk analysis | Insulin | Patients | Furosemide | Screening | Thyroid-stimulating hormone | Pituitary | Ventilation | Birth weight | Health risk assessment
Journal Article
Journal Article
Circulation: Heart Failure, ISSN 1941-3289, 01/2016, Volume 9, Issue 1
Background The prevalence of pre-diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known. We... 
heart failure | Clinical trial | diabetes mellitus | prognosis | treatment outcome | clinical trial | CARDIAC & CARDIOVASCULAR SYSTEMS | PREDICTOR | TOLERANCE | HEMOGLOBIN A(1C) | HOSPITALIZATION | INHIBITION | A1C | INSULIN-RESISTANCE | GLUCOSE | DYSFUNCTION | OUTCOMES | Diabetes Mellitus - blood | Single-Blind Method | Prevalence | Prospective Studies | Ventricular Function, Left | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Heart Failure - physiopathology | Aminobutyrates - adverse effects | Male | Heart Failure - blood | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Heart Failure - diagnosis | Diabetes Mellitus - diagnosis | Diabetes Mellitus - mortality | Prediabetic State - epidemiology | Heart Failure - mortality | Prediabetic State - blood | Risk Assessment | Comorbidity | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Biomarkers - blood | Heart Failure - drug therapy | Prediabetic State - mortality | Prediabetic State - diagnosis | Stroke Volume | Disease-Free Survival | Diabetes Mellitus - epidemiology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Blood Glucose - metabolism | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | 10093 | 10150 | 10094 | Original | glucose | hospitalization | inhibition | Klinisk medicin | dysfunction | Clinical Medicine | a1c | insulin-resistance | hemoglobin a(1c) | Cardiovascular System & Cardiology | predictor | cardiovascular risk | tolerance
Journal Article